Derrick Maley

Statistics

Publications

Citations

700

H-Index

Active since

1986

Affiliations

Bristol-Myers Squibb (United States)(Current)

GlaxoSmithKline (United States)

Johnson & Johnson (United States)

Biocon (India)

DuPont (United States)

Derrick Maley is an author at Bristol-Myers Squibb (United States) specializing in molecular biology, life sciences, and indoleamine 2, 3-dioxygenase pathway.

Publications per year

1986–2021

Publications

Immune-modulating enzyme indoleamine 2,3-dioxygenase is effectively inhibited by targeting its apo-form

Micah T. Nelp, Patrick A. Kates, John T. Hunt et al. · Proceedings of the National Academy of Sciences · 2018 · 208 citations · Full text

Life Sciences, Immunology, Molecular Biology +14

Identification and Biological Characterization of Heterocyclic Inhibitors of the Hepatitis C Virus RNA-dependent RNA Polymerase

Dashyant Dhanak, Kevin J. Duffy, Victor K. Johnston et al. · Journal of Biological Chemistry · 2002 · 196 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Terminal Nucleotidyl Transferase Activity of Recombinant <i>Flaviviridae</i> RNA-Dependent RNA Polymerases: Implication for Viral RNA Synthesis

C. T. Ranjith-Kumar, J. J. GAJEWSKI, Lester L. Gutshall et al. · Journal of Virology · 2001 · 102 citations · Full text

Life Sciences, Microbiology, Molecular Biology +16

Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor

Aaron Balog, Tai-an Lin, Derrick Maley et al. · Molecular Cancer Therapeutics · 2020 · 61 citations · Full text

Medicine, Immunology, Pharmacology +16

Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1

Emily C. Cherney, Liping Zhang, Susheel J. Nara et al. · ACS Medicinal Chemistry Letters · 2021 · 27 citations · Full text

Medicine, Oncology, Pharmacology +13

1–5 of 12